Related Experiment Video
Updated: May 9, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Protein kinase C-δ-mediated recycling of active KIT in colon cancer
Misun Park1, Won Kyu Kim, Meiying Song
1Authors' Affiliations: Departments of Pathology and Brain Korea 21 Projects for Medical Science, Yonsei University College of Medicine; and Department of Biological Sciences, Creative Research Initiative Center for Chromatin Dynamics, Seoul National University, Seoul, South Korea.
Purpose:
Abnormal signaling through receptor tyrosine kinase (RTK) moieties is important in tumorigenesis and drug targeting of colorectal cancers. Wild-type KIT (WT-KIT), a RTK that is activated upon binding with stem cell factor (SCF), is highly expressed in some colon cancers; however, little is known about the functional role of SCF-dependent KIT activation in colon cancer pathogenesis. We aimed to elucidate the conditions and roles of WT-KIT activation in colon cancer tumorigenesis.
Experimental Design:
Colorectal cancers with KIT expression were characterized by immunoblotting and immunohistochemistry. The biologic alterations after KIT-SCF binding were analyzed with or without protein kinase C (PKC) activation.
Results:
We found that WT-KIT was expressed in a subset of colon cancer cell lines and was activated by SCF, leading to activation of downstream AKT and extracellular signal-regulated kinase (ERK) signaling pathways. We also showed that KIT expression gradually decreased, after prolonged SCF stimulation, due to lysosomal degradation. Degradation of WT-KIT after SCF binding was significantly rescued when PKC was activated. We also showed the involvement of activated PKC-δ in the recycling of WT-KIT. We further showed that a subset of colorectal cancers exhibit expressions of both WT-KIT and activated PKC-δ and that expression of KIT is correlated with poor patient survival (P = 0.004).
Conclusions:
Continuous downstream signal activation after KIT-SCF binding is accomplished through PKC-δ-mediated recycling of KIT. This sustained KIT activation may contribute to tumor progression in a subset of colon cancers with KIT expression and might provide the rationale for a therapeutic approach targeting KIT.
Insights
Wild-type KIT (WT-KIT) activation by stem cell factor (SCF) drives colon cancer progression. Protein kinase C-delta (PKC-δ) recycles WT-KIT, sustaining signaling and correlating with poor patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Receptor tyrosine kinase (RTK) aberrant signaling is crucial in colorectal cancer (CRC) tumorigenesis and targeted therapy.
- Wild-type KIT (WT-KIT), an RTK activated by stem cell factor (SCF), is overexpressed in some colon cancers, but its role in pathogenesis is unclear.
Purpose of the Study:
- To investigate the conditions and functional roles of WT-KIT activation in colon cancer development.
- To elucidate the molecular mechanisms regulating WT-KIT stability and signaling in response to SCF.
Main Methods:
- Characterization of KIT expression in colorectal cancers using immunoblotting and immunohistochemistry.
- Analysis of biological alterations following KIT-SCF binding, with and without protein kinase C (PKC) activation.
- Investigation of the role of PKC-δ in WT-KIT regulation and signaling.
Main Results:
- WT-KIT activation by SCF triggers downstream AKT and ERK signaling pathways in colon cancer cells.
- Prolonged SCF stimulation leads to lysosomal degradation of WT-KIT, which is rescued by PKC activation.
- Activated PKC-δ mediates WT-KIT recycling, sustaining downstream signaling.
- Co-expression of WT-KIT and activated PKC-δ in a subset of CRCs correlates with poor patient survival (P = 0.004).
Conclusions:
- PKC-δ-mediated recycling of WT-KIT sustains downstream signaling after KIT-SCF binding.
- This sustained KIT activation may drive tumor progression in a subset of colon cancers.
- Targeting KIT presents a potential therapeutic strategy for these patients.
More Related Videos
15:43Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
Receptor Tyrosine Kinases